Biogen, Sunesis in inflammatory and autoimmune disease pact
Executive Summary
In what it says is the largest corporate alliance in its four-year history, Sunesis Pharmaceuticals (compound Tethering fragment-based technology) is collaborating with biopharmaceutical genetic engineering company Biogen to develop oral drugs to treat inflammatory and autoimmune diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice